Vaxart (OTCMKTS:VXRT) Stock Price Passes Below Two Hundred Day Moving Average – Time to Sell?

Shares of Vaxart, Inc. (OTCMKTS:VXRT) crossed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.62 and traded as low as $0.5301. Vaxart shares last traded at $0.5473, with a volume of 297,131 shares.

Vaxart Stock Performance

The firm has a 50 day simple moving average of $0.62 and a two-hundred day simple moving average of $0.62. The stock has a market cap of $132.91 million, a P/E ratio of 3.65 and a beta of 1.09.

Vaxart (OTCMKTS:VXRT) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The company had revenue of $39.23 million during the quarter, compared to analysts’ expectations of $50.50 million. Vaxart had a return on equity of 61.43% and a net margin of 14.51%.

Hedge Funds Weigh In On Vaxart

Institutional investors and hedge funds have recently bought and sold shares of the stock. Raymond James Financial Inc. increased its stake in Vaxart by 16.9% during the 2nd quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 34,075 shares during the period. Invesco Ltd. raised its position in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after buying an additional 70,568 shares in the last quarter. Creative Planning acquired a new stake in shares of Vaxart in the 2nd quarter worth approximately $33,000. Goldman Sachs Group Inc. acquired a new stake in shares of Vaxart in the 1st quarter worth approximately $31,000. Finally, Jones Financial Companies Lllp boosted its holdings in shares of Vaxart by 276,364.7% in the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock valued at $196,000 after acquiring an additional 478,111 shares in the last quarter. Institutional investors own 18.05% of the company’s stock.

Vaxart Company Profile

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.